- We will send in 10–14 business days.
/images/books/10089816/9781468498448.jpg)
- Publisher: Humana
- Year: 2012
- Pages: 386
- ISBN-10: 1468498444
- ISBN-13: 9781468498448
- Format: 15.2 x 22.9 x 2.1 cm, softcover
- Language: English
- SAVE -10% with code: EXTRA
Cancer Immunotherapy at the Crossroads (e-book) (used book) | bookbook.eu
Reviews
Description
Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 15d.06:50:33
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Publisher: Humana
- Year: 2012
- Pages: 386
- ISBN-10: 1468498444
- ISBN-13: 9781468498448
- Format: 15.2 x 22.9 x 2.1 cm, softcover
- Language: English English
Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
Reviews